- Record: found
- Abstract: found
- Article: not found
A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.
2015
AUC, area under the curve,
CR, complete response,
EGFR, Epidermal growth factor inhibitor,
FISH, Fluorescence in situ hybridization,
Hgb, hemoglobin,
IHC, immunohistochemistry,
IRB, Institutional Review Board,
Mg/dl, milligram/deciliter,
Mg/kg, milligram/kilogram,
PD, progressive disease,
PR, partial response,
RECIST, response evaluation in sold tumors,
TNBC, triple negative breast cancer,
epidermal growth factor inhibitor,
g/dl, grams/deciliter,
metastatic breast cancer,
pacliataxel carboplatin,
triple negative breast cancer
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Women with metastatic triple negative breast cancer (TNBC) can have a poor prognosis with treatment limited to cytotoxic chemotherapy. The identification of effective therapies that may limit exposure to cytotoxic chemotherapy and lead to prolonged survival is an unmet medical need. We tested an inhibitor of the epidermal growth factor receptor, panitumumab in combination with chemotherapy.
Related collections
Author and article information
RECIST, response evaluation in sold tumors,TNBC, triple negative breast cancer,epidermal growth factor inhibitor,g/dl, grams/deciliter,metastatic breast cancer,pacliataxel carboplatin,triple negative breast cancer,AUC, area under the curve,CR, complete response,EGFR, Epidermal growth factor inhibitor,FISH, Fluorescence in situ hybridization,Hgb, hemoglobin,IHC, immunohistochemistry,IRB, Institutional Review Board,Mg/dl, milligram/deciliter,Mg/kg, milligram/kilogram,PD, progressive disease,PR, partial response
RECIST, response evaluation in sold tumors, TNBC, triple negative breast cancer, epidermal growth factor inhibitor, g/dl, grams/deciliter, metastatic breast cancer, pacliataxel carboplatin, triple negative breast cancer, AUC, area under the curve, CR, complete response, EGFR, Epidermal growth factor inhibitor, FISH, Fluorescence in situ hybridization, Hgb, hemoglobin, IHC, immunohistochemistry, IRB, Institutional Review Board, Mg/dl, milligram/deciliter, Mg/kg, milligram/kilogram, PD, progressive disease, PR, partial response